Moreover, the potential function of ROS in annexin V change of TG/PHA co-treatment was validated by NAC pretreatment that NAC/TG/PHA treatment showed lower annexin V (+)% than TG/PHA co-treatment in breast cancer cells. The gene discussed is ANXA5; the disease is breast cancer.